What diagnostic workup is recommended for suspected nephritic syndrome in a limited-resource clinic setting?

Diagnostic Workup for Suspected Nephritic Syndrome in Limited-Resource Settings

In a limited-resource clinic setting, prioritize urinalysis with microscopy, serum creatinine, and ANCA/ANA/anti-GBM antibody testing, while excluding infection before considering any immunosuppression. 1

Initial Clinical Assessment

Focus your evaluation on these specific elements:

History:

• Timing of antecedent pharyngitis (1-2 weeks prior) or skin infections (4-6 weeks prior) suggesting post-infectious glomerulonephritis 1
• Rapid decline in kidney function (days to weeks) suggesting rapidly progressive glomerulonephritis
• Systemic symptoms: fever, rash, joint pain, or respiratory symptoms that may indicate vasculitis or lupus

Physical Examination:

• Blood pressure measurement (hypertension is characteristic) 2
• Edema assessment
• Active skin or throat infections
• Signs of systemic vasculitis (rash, purpura, joint swelling)

Essential Laboratory Testing

First-Line Tests (Minimum Required):

Urinalysis with microscopy - This is your most critical test:

• Urine dipstick for protein and blood
• Microscopic examination for glomerular hematuria (dysmorphic RBCs) and/or RBC casts - these findings confirm glomerular disease 1
• Rule out urinary tract infection

Serum creatinine/eGFR:

• Establishes baseline kidney function
• Identifies rapidly progressive disease (critical for management decisions) 1

Complement levels (C3, C4):

• Low C3 suggests post-infectious GN or lupus nephritis
• Persistently low C3 beyond 12 weeks requires kidney biopsy to exclude C3 glomerulonephritis 1

Second-Line Serologic Testing (If Available):

Autoimmune serologies - obtain these while awaiting other results 1:

• ANCA (MPO and PR3) - most important for detecting ANCA-associated vasculitis, the most common cause of rapidly progressive kidney failure
• ANA - screens for lupus nephritis
• Anti-GBM antibodies - identifies anti-GBM disease

Infection markers:

• Anti-streptolysin O (ASO), anti-DNAse B for post-streptococcal GN 1
• Blood cultures if endocarditis or bacteremia suspected
• Hepatitis B and C serology in adults with proteinuric disease 1

Critical Decision Points

When to Start Treatment Before Biopsy:

If clinical presentation is compatible with small-vessel vasculitis AND MPO- or PR3-ANCA is positive, do NOT delay immunosuppressive therapy waiting for kidney biopsy. 1 The same applies if anti-GBM antibody disease or lupus nephritis is suspected in rapidly progressive disease.

However, you must exclude infection with as much certainty as possible before giving significant immunosuppression. 1 This is a critical pitfall - immunosuppressing an infected patient can be catastrophic.

When Kidney Biopsy is Essential:

While biopsy provides diagnostic confirmation and prognostic information, it should be pursued when feasible but not delay treatment in the scenarios above 1. Biopsy is particularly useful when:

• ANCA-negative but high clinical suspicion for vasculitis
• Diagnosis uncertain
• Culture evidence of infection is elusive in suspected infection-related GN 1
• Persistently low C3 beyond 12 weeks 1

Common Diagnostic Patterns in Limited Settings

Based on epidemiologic data, expect these diagnoses most frequently 3:

• IgA nephropathy (~38% of nephritic syndrome cases globally)
• Lupus nephritis (~8%)
• Post-infectious glomerulonephritis (especially in children and resource-limited areas)
• ANCA-associated vasculitis (most common cause of rapidly progressive disease)

Practical Algorithm for Limited Resources:

1. Confirm nephritic syndrome: Urinalysis showing glomerular hematuria + proteinuria + elevated creatinine
2. Exclude infection: Cultures, clinical assessment
3. Assess urgency: Is this rapidly progressive (creatinine rising over days-weeks)?
4. Send autoimmune serologies: ANCA, ANA, anti-GBM, complement levels
5. If ANCA-positive with compatible presentation: Start immunosuppression immediately, arrange biopsy when feasible
6. If ANCA-negative or unclear: Pursue biopsy before immunosuppression if possible
7. Monitor C3: If low and not normalized by 12 weeks, biopsy is needed 1

Key Pitfalls to Avoid:

• Never delay treatment in ANCA-positive rapidly progressive GN - waiting for biopsy can result in irreversible kidney damage 1
• Never start immunosuppression without excluding infection - this can be fatal 1
• Don't assume post-infectious GN without complement testing - persistently low C3 suggests alternative diagnosis 1
• Don't overlook systemic symptoms - extrarenal manifestations guide diagnosis and urgency 1

The diagnostic strategy must balance the need for definitive diagnosis against the urgency of treatment in rapidly progressive disease, with infection exclusion being the absolute priority before immunosuppression.